CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Aura Biosciences, Inc. (AURA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Aura Biosciences, Inc. (AURA)

Biological Products, (No Diagnostic Substances) · market cap $627M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-30 (est.)
Phase 2
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Aura Biosciences (AURA) is a 106-employee biotech with a ~$641M market cap (~$6.18/share). Its lead asset, Bel-sar, is in Phase 3 for choroidal melanoma, and the pipeline also lists AU-011 entries in Phase 2 for eye cancer and uveal melanoma. The setup is dominated by a financing question: our data shows $67.8M of cash and 6.3 months of runway against a 2025 net loss of $106M.
The catalyst path
  • 2026-11-30 (est.)Phase 2 · AU-011imp 7/10
  • 2027-11-15 (est.)Phase 3 · Bel-sarimp 9/10
Pipeline
AssetPhaseIndication
Bel-sarPhase 3Choroidal Melanoma
Light-activated AU-011Phase 2Uveal Melanoma
AU-011Phase 2Eye Cancer
Price & technical context
3-month
-12.0%
6-month
-3.9%
12-month
+29.8%
52-wk range
$4.97–$8.90
vs 50-day MA
+9.9%
vs 200-day MA
+5.6%
Realized vol
56.9%
Max drawdown
-57.9%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for AURA (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.